No Data
Yifang Biotech 2024 Annual Results Pre-loss Announcement
InventisBio (SHSE:688382) Is In A Good Position To Deliver On Growth Plans
Express News | Inventisbio Announces Positive Phase 2 Study Results for D-2570 (Tyk2 Inhibitor) in Patients With Moderate to Severe Plaque Psoriasis
InventisBio Announces Positive Phase 2 Study Results for D-2570 (TYK2 Inhibitor) in Patients With Moderate to Severe Plaque Psoriasis
Yifang Biotechnology (688382.SH): D-2570 Phase II clinical trial achieved positive clinical trial results.
On December 3, Glonghui reported that Yifang Bio (688382.SH) announced that its self-developed targeted TYK2 novel oral selective inhibitor D-2570 has recently completed a Phase II clinical trial for psoriasis, achieving positive clinical trial results. This trial is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study aimed at assessing the efficacy and safety of D-2570 in treating moderate to severe plaque psoriasis. According to the trial protocol, a total of 161 psoriasis patients were recruited for the trial, divided into groups to take three different doses of D-2570 and a placebo. The main results of the trial are...
InventisBio Co., Limited's (SHSE:688382) Market Cap Dropped CN¥1.1b Last Week; Retail Investors Bore the Brunt